摘要
目的研究帕金森氏病行多巴胺受体激动剂普拉克索的治疗效果。方法回顾分析我院2015年5月—2016年5月收治的98例帕金森氏病患者临床资料,按用药方式不同分2组,对照组(44例)行美多芭+帕罗西汀治疗,观察组(54例)行普拉克索治疗,对比组间疗效及不良反应。结果治疗后,观察组显效39例,有效12例,无效3例;对照组显效23例,有效10例,无效11例;观察组总有效率94.44%(51/54)比对照组75.00%(33/44)高(P<0.05);观察组治疗后恶心呕吐2例(3.70%),对照组恶心呕吐1例(2.27%),头晕1例(2.27%);两组不良反应率对比无统计差异(P>0.05)。结论帕金森氏病通过多巴胺受体激动剂-普拉克索治疗后可显著改善疾病症状,抗抑郁,无严重不良反应。
Objective To study the therapeutic effect of paclitaxel on dopamine receptor agonist in Parkinson＇s disease. Methods The clinical data of 98 patients with Parkinson＇s disease admitted in our hospital from May 2015 to May 2016 were divided into two groups according to the different treatment methods. The control group（44 cases） was treated with methadopa ＋ paroxetine and the observation group（54 cases） treated with pramipexole, compared between the efficacy and adverse reactions. Results After treatment, the observation group was effective in 39 cases, effective in 12 cases, ineffective in 3 cases; control group markedly effective in 23 cases, effective in 10 cases, 11 cases; the total effective rate of 94.44%（51/54） than the control group 75.00%（P 〈 0.05）. In the observation group, 2 cases（3.70%） were nausea and vomiting, 1 case（2.27%） was nausea and vomiting, 1 case（2.27%） was dizziness in the control group and no adverse reaction rate differences（P 〉 0.05）.Conclusion Parkinson＇s disease through the dopamine receptor agonist-pramipexole treatment can significantly improve disease symptoms, antidepressant, no serious adverse reactions.
出处
《中国卫生标准管理》
2017年第14期66-67,共2页
China Health Standard Management
